Abstract: The invention relates to PGT121-germline-targeting designs, trimer stabilization designs, combinations of those two, trimers designed with modified surfaces helpful for immunization regimens, other trimer modifications and on development of trimer nanoparticles and methods of making and using the same.
Type:
Grant
Filed:
September 24, 2018
Date of Patent:
December 21, 2021
Assignees:
INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
Inventors:
Jon Steichen, Dan Kulp, Xiaozhen Hu, Sergey Menis, William Schief, Sebastian Raemisch
Abstract: Disclosed herein are compositions comprising arenavirus monoclonal antibodies, as well as therapeutic, diagnostic, and preventative methods using the novel antibodies. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules, peptides) that inhibit Old World arenavirus infectivity, including LASV and LCMV. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains. Diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses are also disclosed, as well as new tools and methods for the design, production, and use of arenavirus monoclonal antibodies, including expression in engineered bacterial- and mammalian-based systems.
Type:
Grant
Filed:
December 5, 2017
Date of Patent:
December 14, 2021
Inventors:
Luis M. Branco, Robert F. Garry, James E. Robinson, Erica O. Saphire, Kathryn M. Hastie, Thomas W. Geisbert
Abstract: This disclosure provides a method for preventing, treating, or managing an ebolavirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one pan-ebolavirus internal fusion loop antibody or antigen-binding fragment thereof, wherein the binding domain specifically binds to the epitope on two or more ebolavirus species or strains.
Type:
Grant
Filed:
October 9, 2017
Date of Patent:
November 30, 2021
Assignees:
INTEGRATED BIOTHERAPEUTICS, INC., UNIVERSITY OF MARYLAND, COLLEGE PARK
Inventors:
Mohammad Javad Aman, Katie A. Howell, Frederick Wayne Holtsberg, Xuelian Zhao, Yuxing Li
Abstract: Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.
Type:
Grant
Filed:
October 9, 2020
Date of Patent:
November 23, 2021
Assignee:
IncellDx, Inc.
Inventors:
Edgar B. Francisco, Hallison Rodrigues, Amruta Pise, Bruce K. Patterson
Abstract: The invention contemplates a new synthetic, codon-optimized Sin Nombre virus (SNV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The SNV ORF was cloned into a plasmid to form the first stable recombinant SNV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a vaccine system, and is useful to protect mammals against infection with Sin Nombre virus.
Abstract: The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.
Type:
Grant
Filed:
October 10, 2014
Date of Patent:
October 26, 2021
Assignee:
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
Type:
Grant
Filed:
September 23, 2019
Date of Patent:
October 26, 2021
Assignees:
THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
Inventors:
Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
Abstract: Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
Type:
Grant
Filed:
December 7, 2017
Date of Patent:
October 19, 2021
Assignees:
THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
Inventors:
Ron Diskin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman
Abstract: Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick C1 (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.
Type:
Grant
Filed:
June 19, 2019
Date of Patent:
October 19, 2021
Assignee:
Albert Einstein College of Medicine
Inventors:
Kartik Chandran, Anna Z. Wec, Elisabeth K. Nyakatura, Jonathan R. Lai
Abstract: This invention relates to novel anti-HIV antibodies that can be used in the treatment and detection of human immunodeficiency virus (HIV). These antibodies exhibit a high degree of sensitivity and can provide a broad range of specificity.
Type:
Grant
Filed:
September 24, 2016
Date of Patent:
October 12, 2021
Assignee:
AbVitro LLC
Inventors:
Francois Vigneault, Adrian Wrangham Briggs, Stephen J. Goldfless, Sonia Timberlake
Abstract: The present invention provides highly efficient methods, and compositions related thereto, for generating high titer human antibodies or antibody fragments thereof in a mammalian subject. The methods comprise administering a virus or virus-like particle to a mammal comprising heterologous immune cells and isolating a population of immunoglobulin-producing cells from the mammal, thereby producing the antibodies or antibody fragments thereof.
Abstract: The present invention relates to anti-HW antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immuno suppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
Type:
Grant
Filed:
July 10, 2019
Date of Patent:
October 12, 2021
Assignees:
THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGY
Inventors:
Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
Abstract: Provided herein are methods of incorporating substitutions of specified residues into a filovirus GP in order to increase immunogenicity and/or broaden the cross-reactivity of the protective immune response against other filovirus members. Also provided herein are mutant filovirus GPs comprising such substitutions.
Type:
Grant
Filed:
March 27, 2017
Date of Patent:
October 5, 2021
Assignees:
INTEGRATED BIOTHERAPEUTICS, INC., INTEGRAL MOLECULAR, INC.
Inventors:
Mohammad Javad Aman, Katie A. Howell, Edgar Davidson, Benjamin J. Doranz
Abstract: The present invention is directed to recombinant lentiviral particles that array the SARS-CoV-2 spike (S) protein on their surface (“SARS-CoV-2 S Protein Lentiviral Particles”), and that optionally comprise an additional copy of a polynucleotide encoding the SARS-CoV-2 spike (S) protein in their viral genome, and to methods for the production of such lentiviral particles. The invention particularly pertains to such SARS-CoV-2 S Protein Lentiviral Particles that have been engineered to be incapable of mediating the integration of their lentiviral genome into the chromosomes of infected cells and/or to be incapable of mediating the reverse transcription of their lentiviral genome. The present invention is also directed to “SARS-CoV-2 S Protein Lentiviral Vaccine” pharmaceutical compositions that comprise such SARS-CoV-2 S Protein Lentiviral Particles.
Abstract: Provided herein are HIV-1-specific transforming antibodies (tAbs) and antigens that are recognized by HIV-1-specific tAbs. Also provided herein are methods for screening and/or generating HIV-1-specific tAbs and uses of tAbs for prevention and treatment of HIV-1 infection.
Abstract: The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient.
Abstract: A kit, composition and method for detection of antibodies to severe acute respiratory syndrome related coronavirus (SARSr-CoV), and for diagnosis of SARSr-CoV infection.
Abstract: A method for determining HIV-1 co-receptor tropism in an HIV-infected patient includes preparing an HIV-1 envelope protein coding sequence from a sample, introducing the HIV-1 envelope protein coding sequence into a first expression construct using yeast homologous recombination, and using the first expression construct in a cell to cell fusion assay to determine HIV-1 co-receptor tropism.
Type:
Grant
Filed:
May 14, 2019
Date of Patent:
August 31, 2021
Assignee:
CASE WESTERN RESERVE UNIVERISTY
Inventors:
Eric J. Arts, Alison Laing Wright, Kevin V. King, Miguel E. Quinones-Mateu
Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.
Type:
Grant
Filed:
July 1, 2019
Date of Patent:
August 24, 2021
Assignee:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
Vincent C. Bond, Michael Powell, Ming Bo Huang, Syed Ali
Abstract: Compositions and methods of use are provided to boost a primed immune response to HIV. More specifically, the present invention relates to vaccine compositions comprising an HIV-protein boost or an MVA-expressed Env protein and methods of use. Exemplary HIV proteins for protein boosts include proteins such as gp120 proteins B.63521?11mutC and full-length single chain (FLSC), which has been modified to stabilize a CD4-induced Env structure. Exemplary MVAs expressing secreted Methods of administration and dosing regimens are also provided.